Article: Case studies of Big Pharma's sharp practice: Turf wars.(Health Hazard)

UNTIL 1999 pharma giant Novartis enjoyed a monopoly for the drug cyclosporine, used to prevent organ rejection in kidney, liver and heart transplant patients.

But when rivals started producing generic versions, and selling them at a fraction of the price to cash-strapped public-health authorities in Latin America, Novartis went into overdrive.

It began legal proceedings to force Abbott Laboratories to withdraw their generic version, Gengraf, from the market, claiming that Abbott was using microemulsion technology invented and patented by Novartis.

Then, rumours started flying that the generic drugs could be dangerous, even lethal to patients. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!